[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. [2] Muzaffar J, Bari S, Kirtane K, et al. Recent advances and future directions in clinical management of head and neck squamous cell carcinoma[J]. Cancers, 2021, 13(2):338. [3] Xing DT, Khor R, Gan H, et al. Recent research on combination of radiotherapy with targeted therapy or immunotherapy in head and neck squamous cell carcinoma:A review for radiation oncologists[J]. Cancers, 2021, 13(22):5716. [4] Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer[J]. Nat Rev Cancer, 2018, 18(5):269-282. [5] Bos T, Ratti JA, Harada H. Targeting stress-response pathways and therapeutic resistance in head and neck cancer[J]. Front Oral Health, 2021, 2:676643. [6] Kitamura N,Sento S, Yoshizawa Y, et al. Current trends and future prospects of molecular targeted therapy in head and neck squamous cell carcinoma[J]. Int J Mol Sci, 2020, 22(1):240. [7] Wang M,Xu ZC, Kong YZ. The tubby-like proteins kingdom in animals and plants[J]. Gene, 2018, 642:16-25. [8] Nishina PM, North MA, Ikeda A, et al. Molecular characteriza-tion of a novel tubby gene family member, TULP3, in mouse and humans[J]. Genomics, 1998, 54(2):215-220. [9] Patterson VL, Damrau C, Paudyal A, et al. Mouse hitchhiker mutants have spina bifida, dorso-ventral patterning defects and polydactyly:Identification of Tulp3 as a novel negative regulator of the Sonic hedgehog pathway[J]. Hum Mol Genet, 2009, 18(10):1719-1739. [10] Hirano T,Katoh Y, Nakayama K. Intraflagellar transport-A complex mediates ciliary entry and retrograde trafficking of ciliary G protein-coupled receptors[J]. Mol Biol Cell, 2017, 28(3):429-439. [11] Sartor ITS, Recamonde-Mendoza M, Ashton-Prolla P. TULP3:A potential biomarker in colorectal cancer?[J]. PLoS One, 2019, 14(1):e0210762. [12] Sartor ITS, Zeidán-Chuliá F, Albanus RD, et al. Computational analyses reveal a prognostic impact of TULP3 as a transcriptional master regulator in pancreatic ductal adenocarcinoma[J]. Mol Biosyst, 2014, 10(6):1461-1468. [13] Scanlon CS, van Tubergen EA, Inglehart RC, et al. Biomarkers of epithelial-mesenchymal transition in squamous cell carcinoma[J]. J Dent Res, 2013, 92(2):114-121. [14] Yeung KT, Yang J. Epithelial-mesenchymal transition in tumor metastasis[J]. Mol Oncol, 2017, 11(1):28-39. [15] Smith A,Teknos TN, Pan Q. Epithelial to mesenchymal transition in head and neck squamous cell carcinoma[J]. Oral Oncol, 2013, 49(4):287-292. [16] Baumeister P, Zhou JF, Canis M, et al. Epithelial-to-mesenchy-mal transition-derived heterogeneity in head and neck squamous cell carcinomas[J]. Cancers, 2021, 13(21):5355. [17] Malumbres M. Cyclin-dependent kinases[J]. Genome Biol, 2014, 15(6):122. [18] Bertoli C, Skotheim JM, de Bruin RAM. Control of cell cycle transcription during G1 and S phases[J]. Nat Rev Mol Cell Biol, 2013, 14(8):518-528. [19] Malumbres M, Barbacid M. Cell cycle, CDKs and cancer:A changing paradigm[J]. Nat Rev Cancer, 2009, 9(3):153-166. [20] Suski JM, Braun M, Strmiska V, et al. Targeting cell-cycle machinery in cancer[J]. Cancer Cell, 2021, 39(6):759-778. |